Validation Study of Physical Measurement of Tophi
|ClinicalTrials.gov Identifier: NCT00175006|
Recruitment Status : Completed
First Posted : September 15, 2005
Results First Posted : July 16, 2009
Last Update Posted : July 27, 2010
|Condition or disease||Intervention/treatment||Phase|
|Gout||Other: Measurement of Tophi to validate procedure||Phase 2|
Gout is a chronic urate crystal deposition disorder. Left untreated, gout may result in progressive disease characterized by joint and bone destruction from tophaceous deposits and renal impairment due to gouty nephropathy. Hyperuricemia, defined as a serum urate concentration greater than 7.0 milligrams per deciliter (mg/dL), is the underlying metabolic aberration leading to urate crystal deposition in gout. Gout has several clinical presentations, including: recurrent acute attacks of inflammatory arthritis; deposition of monosodium urate monohydrate crystals in joints, bones and even parenchymal organs (tophaceous gout); renal impairment; and uric acid nephrolithiasis.1 As serum urate levels increase beyond greater than 7.0 mg/dL, the risks for gouty arthritis or for renal calculi increase.
Febuxostat is a 2-aryl-thiazole derivative chemically engineered as a novel xanthine oxidase/dehydrogenase inhibitor. Febuxostat is being developed as an orally administered agent for the management of hyperuricemia in patients with gout.
Subjects with palpable tophi >10 millimeters (mm) in length and width and as round as possible will have the tophus measured on two separate visits by two different raters to assess the inter- and intra-rater reproducibility of direct physical measurement.
|Study Type :||Observational|
|Actual Enrollment :||13 participants|
|Official Title:||A Study to Assess a Direct Physical Measurement Method for Evaluation of Tophus Nodules in Subjects With Gout.|
|Study Start Date :||November 2002|
|Primary Completion Date :||January 2003|
|Study Completion Date :||January 2003|
Other: Measurement of Tophi to validate procedure
Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
- Average Percent Difference in Area Between Visits [ Time Frame: Visit 1 (Day 1) and Visit 2 (Days 6-11) ]The rater measured length and width (mm) of the tophus at 2 visits separated by no more than 10 days. Area of the tophus was summarized using average percent difference, calculated as absolute difference of Visits 1 and 2 divided by the average of Visits 1 and 2 for the same tophus, pooled across raters.
- Average Percent Difference in Area Between Raters [ Time Frame: Visit 1 (Day 1 ) and Visit 2 (Day 6-11) ]Each rater measured length and width (mm) of the tophus at 2 visits separated by no more than 10 days. Area of the tophus was summarized using the average percent difference, calculated as the absolute difference of Raters 1 and 2 divided by the average of Raters 1 and 2 for the same tophus, pooled across visits.
Biospecimen Retention: None Retained
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00175006
|Study Director:||Medical Director||Takeda|